The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1175
February 2, 2004
View Complete Issue         Table of Contents 2019 
Daptomycin (Cubicin) for Skin and Soft Tissue Infections
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Daptomycin (Cubicin) for Skin and Soft Tissue Infections
February 2, 2004 (Issue: 1175)
Daptomycin (Cubicin - Cubist), a cyclic lipopeptide (a new class of antibiotics), has been approved by the FDA for intravenous (IV) treatment of complicated skin and skin structure infections. It is being promoted as a once-daily bactericidal...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Daptomycin (Cubicin) for Skin and Soft Tissue Infections
Article code: 1175c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.